Literature DB >> 17303574

Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells.

Yusuf Baran1, Arelis Salas, Can E Senkal, Ufuk Gunduz, Jacek Bielawski, Lina M Obeid, Besim Ogretmen.   

Abstract

In this study, mechanisms of resistance to imatinib-induced apoptosis in human K562 cells were examined. Continuous exposure to stepwise increasing concentrations of imatinib resulted in the selection of K562/IMA-0.2 and -1 cells, which expressed approximately 2.3- and 19-fold resistance, respectively. Measurement of endogenous ceramides by high performance liquid chromatography/mass spectroscopy showed that treatment with imatinib increased the generation of ceramide, mainly C18-ceramide, which is generated by the human longevity assurance gene 1 (hLASS1), in sensitive, but not in resistant cells. Inhibition of hLASS1 by small interfering RNA partially prevented imatinib-induced cell death in sensitive cells. In reciprocal experiments, overexpression of hLASS1, and not hLASS6, in drug-resistant cells caused a marked increase in imatinib-induced C18-ceramide generation, and enhanced apoptosis. Interestingly, there were no defects in the levels of mRNA and enzyme activity levels of hLASS1 for ceramide generation in K562/IMA-1 cells. However, expression levels of sphingosine kinase-1 (SK1) and generation of sphingosine 1-phosphate (S1P) were increased significantly in K562/IMA-1 cells, channeling sphingoid bases to the sphingosine kinase pathway. The partial inhibition of SK1 expression by small interference RNA modulated S1P levels and increased sensitivity to imatinib-induced apoptosis in resistant cells. On the other hand, forced expression of SK1 in K562 cells increased the ratio between total S1P/C18-ceramide levels approximately 6-fold and prevented apoptosis significantly in response to imatinib. Additional data indicated a role for SK1/S1P signaling in the up-regulation of the Bcr-Abl expression at the post-transcriptional level, which suggested a possible mechanism for resistance to imatinib-mediated apoptosis. In conclusion, these data suggest a role for endogenous C18-ceramide synthesis mainly via hLASS1 in imatinib-induced apoptosis in sensitive cells, whereas in resistant cells, alterations of the balance between the levels of ceramide and S1P by overexpression of SK1 result in resistance to imatinib-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17303574     DOI: 10.1074/jbc.M610157200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  84 in total

1.  Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation.

Authors:  Yusuf Baran; Jacek Bielawski; Ufuk Gunduz; Besim Ogretmen
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-11       Impact factor: 4.553

Review 2.  The role of the ceramide acyl chain length in neurodegeneration: involvement of ceramide synthases.

Authors:  Oshrit Ben-David; Anthony H Futerman
Journal:  Neuromolecular Med       Date:  2010-05-26       Impact factor: 3.843

3.  Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.

Authors:  Melda Comert; Yusuf Baran; Guray Saydam
Journal:  Am J Blood Res       Date:  2013-08-19

4.  Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells.

Authors:  Andrew J Kennedy; Thomas P Mathews; Yugesh Kharel; Saundra D Field; Morgan L Moyer; James E East; Joseph D Houck; Kevin R Lynch; Timothy L Macdonald
Journal:  J Med Chem       Date:  2011-05-02       Impact factor: 7.446

5.  Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro.

Authors:  Giulia Marvaso; Agnese Barone; Nicola Amodio; Lavinia Raimondi; Valter Agosti; Emanuela Altomare; Valerio Scotti; Angela Lombardi; Roberto Bianco; Cataldo Bianco; Michele Caraglia; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal:  Cancer Biol Ther       Date:  2014-03-21       Impact factor: 4.742

6.  Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

Authors:  Vladimir Beljanski; Christian Knaak; Yan Zhuang; Charles D Smith
Journal:  Invest New Drugs       Date:  2010-05-18       Impact factor: 3.850

7.  Resveratrol induces apoptosis of leukemia cell line K562 by modulation of sphingosine kinase-1 pathway.

Authors:  Hongying Tian; Zhongcui Yu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

8.  Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival.

Authors:  S Wotton; A Terry; A Kilbey; A Jenkins; P Herzyk; E Cameron; J C Neil
Journal:  Oncogene       Date:  2008-06-16       Impact factor: 9.867

Review 9.  Sphingosine-1-phosphate: the Swiss army knife of sphingolipid signaling.

Authors:  Michael Maceyka; Sheldon Milstien; Sarah Spiegel
Journal:  J Lipid Res       Date:  2008-11-05       Impact factor: 5.922

10.  Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells.

Authors:  S Sobue; S Nemoto; M Murakami; H Ito; A Kimura; S Gao; A Furuhata; A Takagi; T Kojima; M Nakamura; Y Ito; M Suzuki; Y Banno; Y Nozawa; T Murate
Journal:  Int J Hematol       Date:  2008-02-20       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.